DERMTECH INC (DMTK) Stock Price, Forecast & Analysis
NASDAQ:DMTK • US24984K1051
DMTK Key Statistics, Chart & Performance
The current stock price of DMTK is 0.094 USD. In the past month the price decreased by -73.14%. In the past year, price decreased by -96.38%.
DMTK Technical Analysis
DMTK Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DMTK. DMTK has a bad profitability rating. Also its financial health evaluation is rather negative.
DMTK Financial Highlights
Over the last trailing twelve months DMTK reported a non-GAAP Earnings per Share(EPS) of -2.7. The EPS increased by 30.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.04% | ||
| ROE | -224.09% | ||
| Debt/Equity | 0 |
DMTK Forecast & Estimates
6 analysts have analysed DMTK and the average price target is 1.53 USD. This implies a price increase of 1527.66% is expected in the next year compared to the current price of 0.094.
For the next year, analysts expect an EPS growth of 35.19% and a revenue growth 16.8% for DMTK
DMTK Ownership
DMTK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DMTK
Company Profile
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in San Diego, California and currently employs 278 full-time employees. The company went IPO on 2017-06-20. The firm is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. Its technology enhances early melanoma detection by non-invasively detecting genomic markers associated with melanoma to identify higher risk lesions at their earliest stages to rule out melanoma. The company provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. Its DermTech Melanoma Test (the DMT) facilitates the clinical assessment of pigmented skin lesions that raise the concern for melanoma. Its commercial test addresses unmet needs in the diagnostic pathway of pigmented skin lesions, dark-colored patches of skin often referred to as moles. The company markets the DMT under the name Pigmented Lesion Assay (PLA). The company is also focuses on products to assess precancerous genomic changes associated with UV sun exposure.
Company Info
DERMTECH INC
12340 El Camino Real
San Diego CALIFORNIA 92037 US
CEO: John Dobak
Employees: 278
Phone: 18584504222
DERMTECH INC / DMTK FAQ
What does DERMTECH INC do?
DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. The company is headquartered in San Diego, California and currently employs 278 full-time employees. The company went IPO on 2017-06-20. The firm is focused on developing and marketing non-invasive genomics tests to aid in the diagnosis and management of skin cancer, inflammatory skin diseases, and aging-related skin conditions. Its technology enhances early melanoma detection by non-invasively detecting genomic markers associated with melanoma to identify higher risk lesions at their earliest stages to rule out melanoma. The company provides genomic analysis of skin samples collected non-invasively using its Smart Stickers. Its DermTech Melanoma Test (the DMT) facilitates the clinical assessment of pigmented skin lesions that raise the concern for melanoma. Its commercial test addresses unmet needs in the diagnostic pathway of pigmented skin lesions, dark-colored patches of skin often referred to as moles. The company markets the DMT under the name Pigmented Lesion Assay (PLA). The company is also focuses on products to assess precancerous genomic changes associated with UV sun exposure.
What is the current price of DMTK stock?
The current stock price of DMTK is 0.094 USD. The price decreased by -11.32% in the last trading session.
Does DMTK stock pay dividends?
DMTK does not pay a dividend.
How is the ChartMill rating for DERMTECH INC?
DMTK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about DERMTECH INC (DMTK) stock?
6 analysts have analysed DMTK and the average price target is 1.53 USD. This implies a price increase of 1527.66% is expected in the next year compared to the current price of 0.094.
Should I buy DMTK stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DMTK.
What is the expected growth for DMTK stock?
The Revenue of DERMTECH INC (DMTK) is expected to grow by 16.8% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.